PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28688245-7 2017 Evening prednisolone also increased nocturnal insulin levels as compared to run-in (P=0.010). Prednisolone 8-20 insulin Homo sapiens 46-53 27995731-4 2017 MATERIALS AND METHODS: Fifty inpatients prescribed >=20 mg/day prednisolone acutely with (1) finger prick blood glucose level (BGL) >=15 mmol/L or (2) BGLs >=10 mmol/L within the previous 24 hours were randomized to either insulin isophane or glargine before breakfast and insulin aspart before meals. Prednisolone 66-78 insulin Homo sapiens 232-239 27995731-10 2017 We recommend an initial daily insulin dose of 0.5 units/kg bodyweight if not on insulin, a greater than 30% increase in pre-prednisolone insulin dose and larger insulin dose adjustments in patients with prednisolone-induced hyperglycaemia. Prednisolone 203-215 insulin Homo sapiens 30-37 27259402-0 2016 A Single Dose of Prednisolone as a Modulator of Undercarboxylated Osteocalcin and Insulin Sensitivity Post-Exercise in Healthy Young Men: A Study Protocol. Prednisolone 17-29 insulin Homo sapiens 82-89 27321736-0 2016 Effects of prednisolone on energy and fat metabolism in patients with rheumatoid arthritis: tissue-specific insulin resistance with commonly used prednisolone doses. Prednisolone 146-158 insulin Homo sapiens 108-115 27321736-13 2016 However, even at low doses, prednisolone exerts adverse effects on fat metabolism, which could exacerbate insulin resistance and increase cardiovascular risk. Prednisolone 28-40 insulin Homo sapiens 106-113 27321736-14 2016 Attenuated postprandial suppression of fat oxidation, but not lipolysis, suggests that prednisolone causes greater insulin resistance in skeletal muscle than in adipocytes. Prednisolone 87-99 insulin Homo sapiens 115-122 27259402-4 2016 OBJECTIVES: A single dose of prednisolone reduces the rise in ucOC produced by exercise, which partly accounts for the failed increase in insulin sensitivity following exercise. Prednisolone 29-41 insulin Homo sapiens 138-145 26493042-2 2016 Low-dose prednisolone causes insulin resistance that typically manifests as postprandial hyperglycaemia. Prednisolone 9-21 insulin Homo sapiens 29-36 26493042-13 2016 CONCLUSIONS: Prednisolone-induced insulin resistance is not associated with postprandial vascular dysfunction in patients with rheumatoid arthritis. Prednisolone 13-25 insulin Homo sapiens 34-41 25565560-10 2015 Specific insulin regimens for prednisolone-induced hyperglycaemia are needed that recommend more insulin during this time period. Prednisolone 30-42 insulin Homo sapiens 9-16 26543549-4 2015 The combination of oral prednisolone and cyclosporine might be effective in treating type B insulin resistance syndrome, particularly in rituximab-resistant cases. Prednisolone 24-36 insulin Homo sapiens 92-99 25565560-10 2015 Specific insulin regimens for prednisolone-induced hyperglycaemia are needed that recommend more insulin during this time period. Prednisolone 30-42 insulin Homo sapiens 97-104 23933953-10 2013 RESULTS: Compared with placebo, prednisolone 7.5 mg and 30 mg decreased insulin-stimulated capillary recruitment by 9 +- 4% and 17 +- 3%, respectively (p < 0.01). Prednisolone 32-44 insulin Homo sapiens 72-79 26370863-4 2015 Prednisolone administration decreased the eosinophil count and (125)I-insulin binding rate; accordingly, the glycemic control improved. Prednisolone 0-12 insulin Homo sapiens 70-77 23933953-11 2013 In addition, prednisolone 7.5 mg and 30 mg reduced insulin sensitivity (M value) by -11.4 +- 4.5 mumol kg(-1) min(-1) and -25.1 +- 4.1 mumol kg(-1) min(-1) (p < 0.001) and increased postprandial glucose levels by 11 +- 5% and 27 +- 9% (p < 0.001), respectively. Prednisolone 13-25 insulin Homo sapiens 51-58 23933953-13 2013 Prednisolone-induced changes in insulin-stimulated capillary recruitment were associated with insulin sensitivity (r = +0.76; p < 0.001), postprandial glucose concentrations (r = -0.52; p < 0.03) and systolic blood pressure (r = -0.62; p < 0.001). Prednisolone 0-12 insulin Homo sapiens 32-39 23933953-13 2013 Prednisolone-induced changes in insulin-stimulated capillary recruitment were associated with insulin sensitivity (r = +0.76; p < 0.001), postprandial glucose concentrations (r = -0.52; p < 0.03) and systolic blood pressure (r = -0.62; p < 0.001). Prednisolone 0-12 insulin Homo sapiens 94-101 23933953-14 2013 Prednisolone increased resistin concentrations, which were negatively related to insulin-stimulated capillary recruitment (r = -0.40; p = 0.03). Prednisolone 0-12 insulin Homo sapiens 81-88 23933953-17 2013 CONCLUSIONS/INTERPRETATION: Prednisolone-induced impairment of insulin-stimulated capillary recruitment was paralleled by insulin resistance, increased postprandial glucose levels, hypertension and increased circulating resistin concentrations in healthy men. Prednisolone 28-40 insulin Homo sapiens 63-70 23199229-1 2012 BACKGROUND: Glucocorticoids, such as prednisolone, are widely used anti-inflammatory drugs, but therapy is hampered by a broad range of metabolic side effects including skeletal muscle wasting and insulin resistance. Prednisolone 37-49 insulin Homo sapiens 197-204 23506355-5 2013 These results suggest that mechanisms by which prednisolone induce insulin resistance include dysregulation of wnt signalling and immune response processes. Prednisolone 47-59 insulin Homo sapiens 67-74 23670996-0 2013 Effects of low-dose prednisolone on hepatic and peripheral insulin sensitivity, insulin secretion, and abdominal adiposity in patients with inflammatory rheumatologic disease. Prednisolone 20-32 insulin Homo sapiens 59-66 23199229-11 2012 Finally, urinary levels of proteinogenic amino acids at day 1 and of N-methylnicotinamide at day 15 significantly correlated with the homeostatic model assessment of insulin resistance and might represent biomarkers for prednisolone-induced insulin resistance. Prednisolone 220-232 insulin Homo sapiens 241-248 23199229-11 2012 Finally, urinary levels of proteinogenic amino acids at day 1 and of N-methylnicotinamide at day 15 significantly correlated with the homeostatic model assessment of insulin resistance and might represent biomarkers for prednisolone-induced insulin resistance. Prednisolone 220-232 insulin Homo sapiens 166-173 22653558-4 2012 C57BL/6J mice were fed a high-fat diet for 6 wk and treated with either prednisolone (10 mg/kg d) or vehicle for the last 7 d. Insulin sensitivity and blood glucose kinetics were analyzed with state-of-the-art stable isotope procedures in different experimental conditions. Prednisolone 72-84 insulin Homo sapiens 129-136 22972030-6 2012 RESULTS: Compared to placebo, prednisolone treatment tended to lower fasting Angptl4 levels (P = 0.073), raised fasting insulin levels (P = 0.0004) and decreased fasting nonesterified fatty acid concentrations (NEFA) (P = 0.017). Prednisolone 30-42 insulin Homo sapiens 120-127 22972030-7 2012 Insulin infusion reduced Angptl4 levels by 6 % (plasma insulin ~200 pmol/l, P = 0.006) and 22 % (plasma insulin ~600 pmol/l, P < 0.0001), which was attenuated by prednisolone treatment (P = 0.03). Prednisolone 165-177 insulin Homo sapiens 0-7 22972030-8 2012 Prednisolone 7.5 mg and 30 mg dose-dependently decreased insulin-mediated suppression of lipolysis (by 11 +- 5 % and 34 +- 6 % respectively). Prednisolone 0-12 insulin Homo sapiens 57-64 22653558-5 2012 Prednisolone treatment aggravated fasting hyperglycemia and hyperinsulinemia caused by high-fat feeding, resulting in a higher homeostatic assessment model of insulin resistance. Prednisolone 0-12 insulin Homo sapiens 65-72 22653558-6 2012 In addition, prednisolone-treated high-fat diet-fed mice appeared less insulin sensitive by detailed analysis of basal glucose kinetics. Prednisolone 13-25 insulin Homo sapiens 71-78 22653558-9 2012 In addition to elevated insulin levels, prednisolone-treated mice showed a major rise in plasma leptin and fibroblast growth factor 21 levels. Prednisolone 40-52 insulin Homo sapiens 24-31 20124412-9 2010 A 15-day treatment with prednisolone increased AUC(gluc) (P<0.001), despite augmented C-peptide secretion (P=0.05). Prednisolone 24-36 insulin Homo sapiens 89-98 21562755-4 2011 Prednisolone 7.5 mg and prednisolone 30 mg decreased the ability of insulin to suppress endogenous glucose production (by 17 +- 6% and 46 +- 7%, respectively, vs placebo). Prednisolone 0-12 insulin Homo sapiens 68-75 21562755-4 2011 Prednisolone 7.5 mg and prednisolone 30 mg decreased the ability of insulin to suppress endogenous glucose production (by 17 +- 6% and 46 +- 7%, respectively, vs placebo). Prednisolone 24-36 insulin Homo sapiens 68-75 21562755-6 2011 Compared with placebo, prednisolone treatment tended to decrease lipolysis in the fasted state (p = 0.062), but both prednisolone 7.5 mg and prednisolone 30 mg decreased insulin-mediated suppression of lipolysis by 11 +- 5% and 34 +- 6%, respectively. Prednisolone 117-129 insulin Homo sapiens 170-177 21562755-6 2011 Compared with placebo, prednisolone treatment tended to decrease lipolysis in the fasted state (p = 0.062), but both prednisolone 7.5 mg and prednisolone 30 mg decreased insulin-mediated suppression of lipolysis by 11 +- 5% and 34 +- 6%, respectively. Prednisolone 117-129 insulin Homo sapiens 170-177 20185761-2 2010 The present studies were conducted to characterize consequences of chronic treatment with the synthetic glucocorticoid prednisolone on insulin sensitivity and blood glucose kinetics in mice. Prednisolone 119-131 insulin Homo sapiens 135-142 20185761-3 2010 Prednisolone treatment increased fasting blood glucose and plasma insulin concentrations, but this apparently reduced insulin sensitivity could not be confirmed in hyperinsulinemic euglycemic clamp studies. Prednisolone 0-12 insulin Homo sapiens 66-73 20185761-3 2010 Prednisolone treatment increased fasting blood glucose and plasma insulin concentrations, but this apparently reduced insulin sensitivity could not be confirmed in hyperinsulinemic euglycemic clamp studies. Prednisolone 0-12 insulin Homo sapiens 118-125 20185761-6 2010 The increased HGP was accompanied by elevated plasma insulin concentrations, indicating reduced insulin sensitivity of hepatic glucose metabolism in prednisolone-treated mice. Prednisolone 149-161 insulin Homo sapiens 53-60 20185761-6 2010 The increased HGP was accompanied by elevated plasma insulin concentrations, indicating reduced insulin sensitivity of hepatic glucose metabolism in prednisolone-treated mice. Prednisolone 149-161 insulin Homo sapiens 96-103 20185761-10 2010 In conclusion, these results indicate that chronic prednisolone treatment reduces insulin sensitivity of HGP, induces a fasting-like phenotype in fed mice, and perturbs the fed-to-fasting transition. Prednisolone 51-63 insulin Homo sapiens 82-89 17220787-14 2007 CONCLUSIONS: Our results indicate that obesity, distribution of obesity, and prednisolone treatment are the predominant determinants of insulin resistance long term after transplantation. Prednisolone 77-89 insulin Homo sapiens 136-143 17956452-2 2007 METHODS: Antibodies to insulin and insulin receptor were determined in the patient with severe hypoglycaemia before and after the treatment with prednisolone. Prednisolone 145-157 insulin Homo sapiens 23-51 17220787-15 2007 Insulin resistance after renal transplantation could be managed favorably by weight and prednisolone dose reduction, which may reduce cardiovascular disease. Prednisolone 88-100 insulin Homo sapiens 0-7 15894868-0 2005 Hypoglycemia and hyperglycemia due to insulin antibodies against therapeutic human insulin: treatment with double filtration plasmapheresis and prednisolone. Prednisolone 144-156 insulin Homo sapiens 38-45 15894868-0 2005 Hypoglycemia and hyperglycemia due to insulin antibodies against therapeutic human insulin: treatment with double filtration plasmapheresis and prednisolone. Prednisolone 144-156 insulin Homo sapiens 83-90 15894868-4 2005 Treatment with double filtration plasmapheresis and subsequent administration of prednisolone in the second patient reduced such antibodies and resulted in recovery of glycemic control by insulin. Prednisolone 81-93 insulin Homo sapiens 188-195 15579527-9 2004 Lowering daily prednisolone toward 5 mg/d has beneficial effects on insulin action after renal transplantation, but withdrawal of 5 mg prednisolone may not influence IS significantly. Prednisolone 15-27 insulin Homo sapiens 68-75 12965105-9 2003 We also report here the modified method of insulin desensitization using crystalline zinc-insulin with prednisolone tapering. Prednisolone 103-115 insulin Homo sapiens 43-50 12965105-9 2003 We also report here the modified method of insulin desensitization using crystalline zinc-insulin with prednisolone tapering. Prednisolone 103-115 insulin Homo sapiens 90-97 12181386-5 2002 RESULTS: Treatment with prednisolone induced insulin resistance (Homeostasis Model Assessment index: placebo vs. prednisolone: 7.15 +/- 1.63 vs. 17.00 +/- 14.26, p = 0.03), hyperinsulinemia (p = 0.01), and hyperglucagonemia (p = 0.001), whereas growth hormone concentrations were unaffected. Prednisolone 24-36 insulin Homo sapiens 45-52 11845223-6 2002 RESULTS: Prednisolone treatment led to insulin resistance as expected (HOMA-S; prednisolone vs placebo; 1.85 +/- 0.26 vs 1.02 +/- 0.10; p < 0.01) with exaggerated first-phase insulin secretion (3016 +/- 468 pmol/l vs 1688 +/- 207 pmol/l; p < 0.01), suggesting a stable disposition index. Prednisolone 9-21 insulin Homo sapiens 39-46 11845223-7 2002 During baseline, normalized spectral power of serum insulin concentration time-series was reduced during prednisolone exposure compared with placebo (8.40 +/- 0.95 vs 11.79 +/- 1.66; p < 0.05) indicating a disturbed high-frequency oscillatory insulin release. Prednisolone 105-117 insulin Homo sapiens 52-59 11845223-7 2002 During baseline, normalized spectral power of serum insulin concentration time-series was reduced during prednisolone exposure compared with placebo (8.40 +/- 0.95 vs 11.79 +/- 1.66; p < 0.05) indicating a disturbed high-frequency oscillatory insulin release. Prednisolone 105-117 insulin Homo sapiens 246-253 11845223-10 2002 CONCLUSION/INTERPRETATION: Six days of prednisolone treatment resulted in a pertubed high-frequency insulin release in the fasting state whereas the ability of glucose to entrain insulin secretion was preserved. Prednisolone 39-51 insulin Homo sapiens 100-107 10965934-7 2000 The timing of serum insulin elevation approximated that of plasma glucose (3 hours: 14+/-3 microU/mL, p=0.006) and lasted until the end of prednisolone administration (2 weeks: 12+/-2 microU/mL, p=0.044), when compared with basal levels (14+/-3 microU/mL). Prednisolone 139-151 insulin Homo sapiens 20-27 1977953-2 1990 Prednisolone treatment leads to diminution of ACTH and cortisol levels, elevation of glucose, insulin and C-peptide concentrations in plasma compared to prednisolone-untreated patients, producing insignificant effect on plasma levels of STH, vasopressin, aldosterone, area and creatinine. Prednisolone 0-12 insulin Homo sapiens 94-101 8685947-7 1996 The ratio of fasting insulin to glucose, which acts as a marker of peripheral insulin resistance, fell with time after transplantation and was increased by greater body weight, higher prednisolone dose, and lower cyclosporine dose. Prednisolone 184-196 insulin Homo sapiens 21-28 8685947-7 1996 The ratio of fasting insulin to glucose, which acts as a marker of peripheral insulin resistance, fell with time after transplantation and was increased by greater body weight, higher prednisolone dose, and lower cyclosporine dose. Prednisolone 184-196 insulin Homo sapiens 78-85 8869668-4 1996 After prednisolone treatment the most important differences during amino acid infusion were a significantly lower fractional excretion of sodium after 120 min (before prednisolone 26%; after prednisolone-7%; p < 0.05), a more pronounced increase in s-insulin after 120 min (before 118%; after 200%; p < 0.05) and a lower s-potassium. Prednisolone 6-18 insulin Homo sapiens 254-261 8869668-6 1996 It is suggested that the more pronounced the increases in plasma insulin and the decrease in serum potassium are mediators of the increased distal tubular sodium reabsorption during amino acid infusion during prednisolone treatment. Prednisolone 209-221 insulin Homo sapiens 65-72 8412763-1 1993 This study examined the changes in beta-cell response and insulin sensitivity induced by a single overnight dose of 15 mg prednisolone in eight type II diabetic subjects, seven nondiabetic normal controls, and eight subjects with a first-degree type II diabetic relative who were therefore at risk of developing diabetes. Prednisolone 122-134 insulin Homo sapiens 58-65 8412763-6 1993 All three groups showed a significant elevation of clamp steady-state plasma insulin levels following prednisolone, with a median percentage elevation of 46%, 66%, and 31% for normal, at-risk, and diabetic subjects, respectively. Prednisolone 102-114 insulin Homo sapiens 77-84 8412763-7 1993 All three groups showed significant reduction in insulin sensitivity measured by CIGMA following prednisolone of 51%, 41%, and 25% of pre-prednisolone levels in normal, at-risk, and diabetic subjects, respectively, with a significantly greater reduction in normal subjects than in diabetics (P < .02). Prednisolone 97-109 insulin Homo sapiens 49-56 8412763-7 1993 All three groups showed significant reduction in insulin sensitivity measured by CIGMA following prednisolone of 51%, 41%, and 25% of pre-prednisolone levels in normal, at-risk, and diabetic subjects, respectively, with a significantly greater reduction in normal subjects than in diabetics (P < .02). Prednisolone 138-150 insulin Homo sapiens 49-56 1977953-2 1990 Prednisolone treatment leads to diminution of ACTH and cortisol levels, elevation of glucose, insulin and C-peptide concentrations in plasma compared to prednisolone-untreated patients, producing insignificant effect on plasma levels of STH, vasopressin, aldosterone, area and creatinine. Prednisolone 0-12 insulin Homo sapiens 106-115 3899618-8 1985 These results suggested that prednisolone treatment with a smaller dosage as well as with the higher dosage resulted in a carbohydrate intolerance, the main cause of which is located in a postreceptor step (or steps) of insulin action. Prednisolone 29-41 insulin Homo sapiens 220-227 3307788-5 1987 Prednisolone (10 microM) significantly increased both insulin biosynthesis and release, while at 5 microM it was effective in increasing only insulin release. Prednisolone 0-12 insulin Homo sapiens 54-61 30299889-8 2018 Further studies are necessary in order to identify factors underlying the variability in response to insulin therapy and clinical benefits of treatment in hospitalized patients with prednisolone-induced hyperglycaemia. Prednisolone 182-194 insulin Homo sapiens 101-108 6360663-11 1984 As in cultured human lymphocytes, preincubation of U-937 cells with prednisolone results in significantly increased insulin binding. Prednisolone 68-80 insulin Homo sapiens 116-123 4289901-0 1967 Influence of prednisolone and ACTH on the formation of insulin-binding antibodies. Prednisolone 13-25 insulin Homo sapiens 55-62 13929849-0 1962 [Use of prednisolone in a patient with a severe temporary insulin-resistant form of diabetes mellitus associated with the development of an allergic reaction]. Prednisolone 8-20 insulin Homo sapiens 58-65 32647588-5 2020 He was managed successfully with an intensive pulsed combination regimen of cyclophosphamide and plasmapheresis augmented with high doses of prednisolone, which normalized his blood sugar levels without insulin therapy. Prednisolone 141-153 insulin Homo sapiens 203-210 30895163-4 2019 One month later, the patient commenced on prednisolone therapy for the treatment of autoimmune pancreatitis, after which his total insulin dosage increased to a maximum of 52 units/day. Prednisolone 42-54 insulin Homo sapiens 131-138 30895163-5 2019 When the prednisolone dosage was later tapered, the patient"s total dosage of insulin was reduced to 42 units/day. Prednisolone 9-21 insulin Homo sapiens 78-85 30895163-9 2019 Such results suggest that the combination of insulin with an SGLT2 inhibitor may be a viable option for the treatment of diabetic patients on prednisolone therapy. Prednisolone 142-154 insulin Homo sapiens 45-52 33016111-3 2021 He was found to have anti-insulin antibodies and responded clinically to plasmapheresis and immunosuppression with mycophenolate mofetil (MMF)and prednisolone. Prednisolone 146-158 insulin Homo sapiens 26-33 29735021-9 2018 The prednisolone-induced increases in DNLi and SCDi were positively correlated with insulin sensitivity (r = 0.35 and 0.50, respectively). Prednisolone 4-16 insulin Homo sapiens 84-91 29588555-9 2018 While it is possible that there was spontaneous resolution of insulin antibodies, we speculate that his prednisolone and immunosuppressant therapy may have suppressed insulin antibody production. Prednisolone 104-116 insulin Homo sapiens 167-174